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Abstract
Epidemiologic studies indicate a strong inverse correlation between plasma levels of high-density lipoproteins
(HDL) and cardiovascular disease (CVD). The most relevant cardioprotective mechanism mediated by HDL is
thought to be reverse cholesterol transport (RCT). New insights in HDL biology and RCT have allowed the
development of promising agents aimed to increase HDL function and promote atherosclerosis regression. In this
regard, apo-AI analogs and CETP inhibitors dalcetrapib and anacetrapib have aroused a great interest and opened
new expectations in the treatment of CVD.
Introduction
Low levels of high-density lipoproteins (HDL) are among
the strongest, statistically independent risk factors for
cardiovascular disease (CVD). It has been estimated that
a 1 mg/dL increase of HDL-cholesterol in plasma results
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accepted mechanism for this HDL protective effect is the
reverse cholesterol transport (RCT). RCT refers to the
mechanism by which cholesterol excess is transported
from cells of extrahepatic tissues and carried back to the
liver, where it can be eliminated or recycled. There has
been a rising interest in the physiology and pharmacology
of RCT [2]. However, contrary to what has been achieved
in the field of LDL control through statin therapy, phar-
macological modulation of HDL biology has not achieved
a comparable success in the clinical arena. Nevertheless,
this growing burden of knowledge has yielded a new gen-
eration of drugs which are under clinical evaluation and
are able not only to increase HDL levels and function,
but also to achieve a measurable atherosclerotic plaque
regression. Within these drugs, apo-AI Milano analogs
and CETP (Cholesterol ester transfer protein) inhibitors
dalcetrapib and anacetrapib deserve to be highlighted
according to the state-of-the-art clinical evidence.
Reverse cholesterol transport (RCT)
Early in the 80’s it was demonstrated that HDL can act as
an acceptor of cellular cholesterol, the first step in the
pathway known as RCT [3]. Briefly, HDL precursors
(lipid-free apoA-I or lipid-poor pre-b1-HDL) are produced
by the liver, the intestine or are released from lipolysed
VLDL and chylomicrons. PLTP (Phospholipid transfer
protein)-mediated phospholipid transfer facilitates apo-AI
lipidation and the formation of pre-b-HDL [2]. Lecithin
cholesterol acyl-transferase (LCAT) esterifies cholesterol
in HDL [4]. Cholesterol esters, more hydrophobic than
free cholesterol, move into the core of HDL particle, creat-
ing a gradient that enables HDL to accept free cholesterol.
After scavenging cholesterol from peripheral tissues, HDL
transports cholesterol to the liver where it will be excreted
or recycled. The selective uptake of cholesterol esters from
HDL into hepatocytes is mediated by the scavenger recep-
tor B type I (SR-BI) [2], and facilitated by the ATP binding
cassette (ABC) transporters ABCA1 and ABCG1 [4].
However, cholesterol esters may also be transferred from
HDL to other lipoproteins, including chylomicrons, VLDL
and LDL, a process mediated by the CETP. Therefore,
CETP possesses a potential atherogenic role by enhancing
the transfer of cholesterol esters from antiatherogenic lipo-
proteins (HDL) to proaterogenic ones (mainly LDL). A
summary of HDL regulation is shown in the Figure 1.
Effects of HDL
Antiatherosclerotic effects of HDL
Atheromatous plaques are not irreversible lesions.
Indeed, pioneer experimental studies have demonstrated
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streaks and induces regression of atherosclerotic lesions
in cholesterol-fed rabbits [5,6]. Nowadays the global
burden of atheromatous plaques can be measured by
novel image techniques. This technology has made it
possible to demonstrate that in animal models athero-
sclerotic plaques are reduced when HDL function is
enhanced [7], and that pharmacologic treatments
that modulate lipid profile (enhance HDL and decrease
LDL) are able to reduce atherosclerosis progression in
humans [8].
Given the central role of HDL in RCT, HDL is con-
sidered essential in therapeutic strategies aimed to inhi-
bit/regress atherosclerotic lesions [2]. HDL can,
therefore, deplete atherosclerotic plaques through their
ability to promote efflux of cholesterol from lipid-loaded
macrophages [9]. However, HDL is a complex macro-
molecule containing diverse bioactive lipids and a
variety of apolipoproteins and enzymes that could indi-
vidually contribute to specific antiatherogenic effects
[10]. These effects are briefly reviewed in the following
sections.
Anti-inflammatory effects of HDL
Numerous studies suggest that the anti-atherogenic
effects of HDL are also related to their anti-inflamma-
tory properties [10,11]. For instance, in macrophages,
HDL prevents the conversion of progranulin into proin-
flammatory granulins [12]; while in endothelial cells,
HDL inhibits the expression of cell adhesion molecules
VCAM-1, ICAM-1 and E-selectin [13,14]. In animal
models, HDL reduces leukocyte homing to arterial
endothelium [15], and increased HDL levels have been
associated with a decrease of the blood concentration of
proinflammatory molecules both in animal models and
in patients [16,17].
Figure 1 Simplified scheme of reverse cholesterol transport. In the onset and progression of atherosclerotic lesions the uptake of modified
LDL (mainly oxidized LDL or oxLDL) by macrophages through a process mediated by scavenger receptors (i.e. SR-A and CD36) that lead to the
formation of lipid-loaded cells is critical. This seems to be a reversible process, as HDL-mediated RCT can clear cholesterol from vascular tissues
contributing to atherosclerosis regression. HDL acquires cholesterol through a mechanism that involves the receptor SR-BI and transports this
cholesterol back to the liver. However, HDL also exchanges lipids with LDL, a process mediated by the CETP that increases LDL cholesterol cargo
and potentially enhances their atherogenicity.
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HDL lipoproteins are able to counteract LDL oxidation,
which is commonly considered a key event in atherogen-
esis. HDL inhibits the enzymatic and non-enzimatic oxi-
dation of LDL, and exerts indirect antioxidant effects
acting as a “sink” for oxidized products that come from
oxidized LDL and transport them to the liver [18]. The
antioxidant properties of HDL are attributed not only to
apoA-I, the most abundant protein in HDL, but also to
several enzymes including paraoxonase (PON), platelet-
activating factor acetylhydrolase (PAF-AH) and glutation
peroxidase (GPx) [19].
Antithrombotic effect of HDL
Deregulation of haemostasis plays a key role in acute cor-
onary syndromes. Tissue factor activates the extrinsic
coagulation pathway and is essential in atheromatous pla-
que rupture. HDL is able to reduce thrombin-induced
tissue factor expression in endothelial cells [20], to inhibit
platelet activation [21], and to stimulate the activation of
the anticoagulant proteins C and S [22].
HDL increases the release of two major antiathero-
genic/antithrombotic molecules by vascular cells: nitric
oxide (NO) and prostacyclin [23]. HDL not only prevents
the inhibition of endothelial nitric oxide synthase (eNOS)
by oxLDL [24], but also induces per se eNOS [25] leading
to the increase in NO production by the endothelium.
Emerging strategies to increase HDL: apo-AI
Milano and CETP inhibition
Genetics of HDL: apo-AI Milano
Apo-AI Milano is a naturally occurring mutant of apo-AI
first described in 1980 [26]. Paradoxically, carriers of this
mutation have very low HDL cholesterol levels, but no
increase in the risk of heart disease. In apo-AI Milano
arginine in position 173 has been substituted by cysteine.
This extra cysteine confers the capacity to form disulfide
bonds yielding homodimers and heterodimers with apo-
AI [27]. Several studies in rabbits that received recombi-
nant apo-AI Milano suggest that apo-AI Milano could
increase RCT [28], although this has not been observed in
mice expressing apo-AI Milano [29].
CETP and cholesterol efflux to the liver
CETP is synthesized in the liver, spleen, adipose tissue and
macrophages, and circulates in plasma bound to HDL.
The main function of CETP is to facilitate the transport of
cholesterol esters and triglycerides among lipoproteins [2].
It collects cholesterol esters from HDL and exchanges
them for triglycerides from chylomicrons, VLDL and LDL,
and viceversa (Figure 1). Therefore, the net effect of CETP
is proatherogenic. In fact, rare mutations leading to
increased function of CETP have been linked to promote
CVD [30]. On the other hand, genetic deficiency of CETP
leads to marked increase in plasma levels of large HDL
particles, and these HDL have enhanced ability to promote
cholesterol efflux from foam cells [31]. CETP activity is
also inhibited by current lipid-lowering drugs, such as
statins, fibrates and niacin [32]. Thus, this molecule may
be considered as an interesting therapeutical target in
order to prevent cardiovascular disease. However, recent
epidemiological studies seem to challenge the mainstream
consideration of CETP as a proatherogenic stimulus. In
two different large population-based studies, CETP muta-
tion has been associated with greater risk of cardiovascular
disease [33,34].
Emerging drugs to increase HDL function
Apo-AI mimetics
When combined with phospholipids, recombinant apo-AI
Milano (ETC-216) can be given in an intravenous setting.
It has been shown to decrease atherosclerotic plaque size
in animal models [7]. This effect has also been demon-
strated in humans [35]. After five weeks of this intrave-
nous treatment with ETC-216, patients have an increase
of HDL, a remarkable decrease of atheromatous burden
and a subsequent lower cardiovascular morbimortality
[36,37]. In some of these analogs, four phenylalanine resi-
dues make a gastro-resistant molecule which enables its
oral administration [38]. Notably, considerable debate still
exists whether injection of wild-type Apo-AI can be as
effective as this natural variant to stimulate RCT [39-41].
A brief summary on the clinical evidence of infusion of
apo-AI Milano and wild-type apo-AI is shown in the
Table 1.
CETP inhibition
Some CETP inhibitors have been demonstrated to possess
a significant effect to increase HDL and decrease LDL
(Figure 2). Torcetrapib showed an important effect in the
rise of HDL in animal models and in the clinical arena.
Among phase III studies, the ILLUSTRATE trial (910
patients, double-blind, randomized trial) compared torce-
trapib and atorvastatin against atorvastatin alone [42]. It
showed that in the highest quartile of HDL increase, a
higher atherosclerotic regression measured by ultrasound
was observed [42]. However, no benefit was observed in
the whole cohort, and a higher rate of high blood pressure
was noted in the torcetrapib group [42]. This torcetrapib-
linked adverse effect was confirmed in the double-blind,
randomized, ILLUMINATE trial (15067 patients, same
comparative groups). In this trial, a higher overall cardio-
vascular mortality was noted in the torcetrapib group
despite an efficient HDL increase [43]. This was related to
sodium rise, potassium decrease and blood pressure
increase, and therefore the study was stopped, the drug
being withdrawn in the United States and the European
Union [44]. Further studies linked these effects with a
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Page 3 of 8Table 1 Clinical evidence on apo-AI HDL infusion
Study Patients Administration Result
Nicholls et al.,
[36]
47 post-acute coronary events (randomized) Intravenous
Apo-AI Milano
4.6% decrease of lamina elastic interna (measured by ultrasound)
Nissen et al.,
[37]
123 post-acute coronary events (randomized) Intravenous
Apo-AI Milano
4.2% decrease of atheromatous plaque volume (measured by ultrasound)
Tardif et al.,
[40]
183 patients on coronariography (randomized) Intravenous
reconstituted wild-type HDL
3.4% decrease of plaque volume (measured by ultrasound) at follow-up(not
difference at baseline)
Shaw et al.,
[41]
20 patients with claudication who underwent femoral
endarterectomy (randomized)
Intravenous reconstituted wild-
type HDL
Decreased expression of vascular cell adhesion molecule-1 and decreased lipid
content
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8torcetrapib-mediated increase in mineralocorticoid stimu-
lation [45]. However, this effect is not mediated by CETP
inhibition and therefore is not necessarily shared by other
CETP blockers. Therefore, the role of CETP inhibitors dal-
cetrapib [46] and anacetrapib [47] is being evaluated, given
that they seem to increase HDL without the adverse effect
in blood pressure. Ongoing big phase III will eventually
show the potential of these promising drugs.
Dalcetrapib (Figure 2) offers the advantage of a high
pharmacological potency, having 0.4-10 μMI C 50 for the
inhibition of CETP (compared to 19-79 μM of torcetra-
pib). Dalcetrapib is highly specific for the interaction of
cysteine 13 from CETP [32]. Preclinical animal models
showed its capability to increase HDL without a significant
increase in blood pressure [48]. Further clinical trials
demonstrated that it does not possess hypertensive effect
in humans and strengthened the idea that dalcetrapib rises
HDL without any significant increase in blood pressure
[46,49]. Large phase III trials are still ongoing with this
drug. The dal-VESSEL trial will assess the effect of dalce-
trapib in the reduction of atheromatous plaques measured
by PET/TAC and MRI [32]. The dal-OUTCOMES trial
will evaluate the effect of the drug on the cardiovascular
morbimortality of a sample of 15600 high-risk patients
[32].
Anacetrapib (Figure 2) is another CETP inhibitor. It has
an IC50 of 15-57 μM [32]. Its capability to raise HDL with-
out a parallel increase of blood pressure has been demon-
strated in phase I trials [50]. A broader study (589
patients) showed that treatment of anacetrapib and ator-
vastatin 20 mg increased HDL [51]. Anacetrapib, at the
maximum tolerated dose of 300 mg, is able to increase
HDL and decrease LDL. However, this last effect is nota-
bly enhanced when given with statins, reaching a 70%
reduction, without any increase in blood pressure [51].
Based on this synergism strategy, the DEFINE trial will
Figure 2 Chemical structure of torcetrapib, dalcetrapib and anacetrapib.
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Page 5 of 8evaluate the role of anacetrapib on 1623 patients whose
statin treatment has achieved LDL < 100 mg/dl, but hav-
ing HDL < 60 mg/dl [32].
Liver × Receptor (LXR) agonists
There are two LXR isoforms: LXRb, ubiquitously
expressed, and LXRa distributed in a tissue-specific fash-
ion, but mainly in liver and tissues involved in lipid meta-
bolism. LXRs are activated by specific oxidized forms of
cholesterol (oxysterols) such as 24(S)-hydroxycholesterol
and by certain intermediates of the cholesterol biosynth-
esis. Analysis of LXR-deficient mice has revealed a broad
role of this receptor in the regulation of genes involved
in lipid homeostasis [52]. For instance, in mice LXR ago-
nists reduce cholesterol absorption in the intestine due to
the up-regulation of ABCG5 and ABCG8, which increase
the efflux of cholesterol thereby limiting its absoption by
intestinal cells [53]. Most interestingly, ABCA1, a key
transporter in the efflux of cholesterol and phospholipids
from macrophages, is a direct target of LXR [54]. In fact,
treatment with endogenous LXR agonists is able to
increase the RCT from macrophages and foam cells and
thus increase the biliary excretion of this lipid [55]. At
the same time, synthetic LXR agonists are able to prevent
atheromatous plaque formation in mice [56]. However,
these drugs promote the expression of lipogenic genes in
the liver, which increase the levels of triglycerides and
promote hepatic steatosis [57]. For this reason, research
on more selective LXR ligands is an active field of experi-
mental pharmacology.
Scavenger receptor B-1 (SR-BI) inhibitors
SR-BI is a receptor which modulates the hepatic uptake
of cholesterol esters by HDL, VLDL and native LDL.
Mice without SR-BI have increased LDL levels and are
prone to atherosclerosis [58]. However, in humans SR-
BI blockade by ITX5061, a molecule initially character-
ized as a p38 mitogen-activated protein kinase (MAPK)
inhibitor, increases HDL, although this effect seems to
be very transient [59].
Summary
RCT is thought to be one of the most important HDL-
mediated cardioprotective mechanisms. However, con-
trary to what has been achieved with LDL modulation by
statin treatment, this mechanism has not been able to be
modulated by safe and effective drugs to date. In fact, the
beneficial therapeutic effects of raising HDL are proving
difficult to confirm in humans. Recent experimental,
translational and clinical research has yielded new drugs
inspired, in some cases, in variants found in Nature, such
as apo-AI Milano analogs, and CETP inhibitors (dalcetra-
pib and anacetrapib). Low HDL level is the most frequent
lipoprotein abnormality in patients suffering premature
CVD. In this context, ongoing clinical studies with emer-
ging drugs aimed to increase HDL function have aroused
a great interest and opened new expectations in the treat-
ment of CVD.
Acknowledgements
This work was supported by FISS (Health Research Fund, PI080920) and Red
Tematica de Investigación Cardiovascular RECAVA (RD06/0014/1007; RD06/
0014/0027), both from the Instituto de Salud Carlos III (ISCIII).
Author details
1Department of Pharmacology, School of Medicine, Universidad
Complutense de Madrid, Spain.
2Service of Hematology, Hospital Nuestra
Señora de Sonsoles, Ávila, Spain.
3Cardiovascular Research Center (CSIC-
ICCC), IIB-Sant Pau, Barcelona, Spain.
Authors’ contributions
CU and TT undertook the initial review of the literature. SR and TT
conceived the idea of the manuscript. SR, CU, J M-G and TT took part in the
design of the manuscript draft. SR, CU, J M-G and TT built the final version.
All authors read and approved the final manuscript.
Competing interests
Santiago Redondo has given conferences and received honoraria from
Gilead and Merck Sharp & Dohme.
Received: 9 September 2011 Accepted: 10 October 2011
Published: 10 October 2011
References
1. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD,
Jacobs DR Jr, Bangdiwala S, Tyroler HA: High-density lipoprotein
cholesterol and cardiovascular disease. Four prospective American
studies. Circulation 1989, 79:8-15.
2. Julve J, Llaverias G, Blanco-Vaca F, Escolà-Gil JC: Seeking novel targets for
improving in vivo macrophage-specific reverse cholesterol transport:
translating basic science into new therapies for the prevention and
treatment of atherosclerosis. Curr Vasc Pharmacol 2011, 9:220-237.
3. Fielding CJ, Fielding PE: Cholesterol transport between cells and body
fluids. Role of plasma lipoproteins and the plasma cholesterol
esterification system. Med Clin North Am 1982, 66:363-373.
4. Cuchel M, Lund-Katz S, de la Llera-Moya M, Millar JS, Chang D, Fuki I,
Rothblat GH, Phillips MC, Rader DJ: Pathways by which reconstituted
high-density lipoprotein mobilizes free cholesterol from whole body and
from macrophages. Arterioscler Thromb Vasc Biol 2010 30:526-532.
5. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V: High density
lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed
rabbits. Lab Invest 1989, 60:455-461.
6. Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by
high density lipoprotein plasma fraction in the cholesterol-fed rabbit.
J Clin Invest 1990, 85:1234-1241.
7. Ibañez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU,
Santos-Gallego CG, Krause B, Badimon L, Fuster V, Badimon JJ: Rapid
change in plaque size, composition, and molecular footprint after
recombinant apolipoprotein A-I Milano (ETC-216) administration:
magnetic resonance imaging study in an experimental model of
atherosclerosis. J Am Coll Cardiol 2008, 51:1104-1109.
8. Lee JM, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I,
Digby JE, Bannister T, Handa A, Wiesmann F, Durrington PN, Channon KM,
Neubauer S, Choudhury RP: Effects of high-dose modified-release
nicotinic acid on atherosclerosis and vascular function: a randomized,
placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol
2009, 54:1787-1794.
9. Lewis GF: Determinants of plasma HDL concentrations and reverse
cholesterol transport. Curr Opin Cardiol 2006, 21:345-352.
10. Assmann G, Nofer JR: Atheroprotective effects of high-density
lipoproteins. Annu Rev Med 2003, 54:321-341.
11. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM:
Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
Redondo et al. Lipids in Health and Disease 2011, 10:175
http://www.lipidworld.com/content/10/1/175
Page 6 of 812. Okura H, Yamashita S, Ohama T, Saga A, Yamamoto-Kakuta A, Hamada Y,
Sougawa N, Ohyama R, Sawa Y, Matsuyama A: HDL/apolipoprotein A-I
binds to macrophage-derived progranulin and suppresses its conversion
into proinflammatory granulins. J Atheroscler Thromb 2010, 17:568-577.
13. Barter PJ, Baker PW, Rye KA: Effect of high-density lipoproteins on the
expression of adhesion molecules in endothelial cells. Curr Opin Lipidol
2002, 13:285-288.
14. Nofer JR, Geigenmüller S, Göpfert C, Assmann G, Buddecke E, Schmidt A:
High density lipoprotein-associated lysosphingolipids reduce E-selectin
expression in human endothelial cells. Biochem Biophys Res Commun
2003, 310:98-103.
15. Theilmeier G, De Geest B, Van Veldhoven PP, Stengel D, Michiels C, Lox M,
Landeloos M, Chapman MJ, Ninio E, Collen D, Himpens B, Holvoet P: HDL-
associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice.
FASEB J 2000, 14:2032-2039.
16. Puranik R, Bao S, Nobecourt E, Nicholls SJ, Dusting GJ, Barter PJ,
Celermajer DS, Rye KA: Low dose apolipoprotein A-I rescues carotid
arteries from inflammation in vivo. Atherosclerosis 2008, 196:240-247.
17. Yamagishi S, Adachi H, Matsui T, Nakamura K, Enomoto M, Fukami A,
Otsuka M, Kumagae S, Nanjo Y, Imaizumi T: Decreased high-density
lipoprotein cholesterol level is an independent correlate of circulating
tumor necrosis factor-alpha in a general population. Clin Cardiol 2009, 32:
E29-E32.
18. Bowry VW, Stanley KK, Stocker R: High density lipoprotein is the major
carrier of lipid hydroperoxides in human blood plasma from fasting
donors. Proc Natl Acad Sci USA 1992, 89:10316-10320.
19. Podrez EA: Anti-oxidant properties of high-density lipoprotein and
atherosclerosis. Clin Exp Pharmacol Physiol 2010, 37:719-725.
20. Viswambharan H, Ming XF, Zhu S, Hubsch A, Lerch P, Vergères G, Rusconi S,
Yang Z: Reconstituted high-density lipoprotein inhibits thrombin-
induced endothelial tissue factor expression through inhibition of RhoA
and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial
nitric oxide synthase. Circ Res 2004, 94:918-925.
21. Nofer JR, Brodde MF, Kehrel BE: High-density lipoproteins, platelets and
the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol 2010,
37:726-735.
22. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernández JA: High-density
lipoprotein enhancement of anticoagulant activities of plasma protein S
and activated protein C. J Clin Invest 1999, 103:219-227.
23. Rodríguez C, González-Díez M, Badimon L, Martínez-González J:
Sphingosine-1-phosphate: A bioactive lipid that confers high-density
lipoprotein with vasculoprotection mediated by nitric oxide and
prostacyclin. Thromb Haemost 2009, 101:665-673.
24. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ: High density
lipoprotein prevents oxidized low density lipoprotein-induced inhibition
of endothelial nitric-oxide synthase localization and activation in
caveolae. J Biol Chem 2000, 275:11278-11283.
25. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P,
Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW: High-
density lipoprotein binding to scavenger receptor-BI activates
endothelial nitric oxide synthase. Nat Med 2001, 7:853-857.
26. Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW: A-IMilano
apoprotein. Decreased high density lipoprotein cholesterol levels with
significant lipoprotein modifications and without clinical atherosclerosis
in an Italian family. J Clin Invest 1980, 66:892-900.
27. Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Magani D, Sirtori CR:
Isolation and characterization of a cysteine-containing variant of the
apoprotein A-1 from high density lipoprotein. J Clin Invest 1980,
66:901-907.
28. Cimmino G, Ibanez B, Vilahur G, Speidl WS, Fuster V, Badimon L,
Badimon JJ: Up-regulation of reverse cholesterol transport key players
and rescue from global inflammation by ApoA-I(Milano). J Cell Mol Med
2009, 13:3226-3235.
29. Alexander ET, Weibel GL, Joshi MR, Vedhachalam C, de la Llera-Moya M,
Rothblat GH, Phillips MC, Rader DJ: Macrophage reverse cholesterol
transport in mice expressing ApoA-I Milano. Arterioscler Thromb Vasc Biol
2009, 29:1496-501.
30. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR: Increased
coronary heart disease in Japanese-American men with mutation in the
cholesteryl ester transfer protein gene despite increased HDL levels. J
Clin Invest 1996, 97:2917-2923.
31. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR: HDL from CETP-deficient
subjects shows enhanced ability to promote cholesterol efflux from
macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest
2006, 116:1435-1342.
32. Chapman MJ, Le Goff W, Guerin M, Kontush A: Cholesteryl ester transfer
protein: at the heart of the action of lipid-modulating therapy with
statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
Eur Heart J 2010, 31:149-164.
33. Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D’Agostino RB,
Ordovas JM: Association of circulating cholesteryl ester transfer protein
activity with incidence of cardiovascular disease in the community.
Circulation 2009, 120:2414-2420.
34. Mowri HO, Patsch JR, Ritsch A, Föger B, Brown S, Patsch W: High density
lipoproteins with differing apolipoproteins: relationships to postprandial
lipemia, cholesteryl ester transfer protein, and activities of lipoprotein
lipase, hepatic lipase, and lecithin: cholesterol acyltransferase. J Lipid Res
1994, 35:291-300.
35. Nicholls SJ, Uno K, Kataoka Y, Nissen SE: ETC-216 for coronary artery
disease. Expert Opin Biol Ther 2011, 11:387-394.
36. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S,
Niossen SE: Relationship between atheroma regression and change in
lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol
2006, 47:992-997.
37. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M,
Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T,
Blankenship JC, Kerensky R: Effect of recombinant ApoA-I Milano on
coronary atherosclerosis in patients with acute coronary syndromes: a
randomized controlled trial. JAMA 2003, 290:2292-2300.
38. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G,
Lallone R, Fogelman AM: Oral administration of an Apo A-I mimetic
Peptide synthesized from D-amino acids dramatically reduces
atherosclerosis in mice independent of plasma cholesterol. Circulation
2002, 105:290-292.
39. Weibel GL, Alexander ET, Joshi MR, Rader DJ, Lund-Katz S, Phillips MC,
Rothblat GH: Wild-type ApoA-I and the Milano variant have similar
abilities to stimulate cellular lipid mobilization and efflux. Arterioscler
Thromb Vasc Biol 2007, 27:2022-2029.
40. Tardif JC, Grégoire J, L’Allier PL, Ibrahim R, Lespérance J, Heinonen TM,
Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J, Effect of
rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators: Effects
of reconstituted high-density lipoprotein infusions on coronary
atherosclerosis: a randomized controlled trial. JAMA 2007,
297:1675-1682.
41. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N,
Woollard K, Lyon S, Sviridov D, Dart AM: Infusion of reconstituted high-
density lipoprotein leads to acute changes in human atherosclerotic
plaque. Circ Res 2008, 103:1084-1091.
42. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W,
Bachinsky WB, Lasala GP, Tuzcu EM, ILLUSTRATE Investigators: Effect of
torcetrapib on the progression of coronary atherosclerosis. N Engl J Med
2007, 356:1304-1316.
43. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M,
Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH,
Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators: Effects of
torcetrapib in patients at high risk for coronary events. N Engl J Med
2007, 357:2109-2122.
44. Psaty BM, Lumley T: Surrogate end points and FDA approval: a tale of 2
lipid-altering drugs. JAMA 2008, 299:1474-1476.
45. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, Yuan H, Perry DA,
Keiser J: Torcetrapib induces aldosterone and cortisol production by an
intracellular calcium-mediated mechanism independently of cholesteryl
ester transfer protein inhibition. Endocrinology 2009, 150:2211-2219.
46. Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG: Safety and
tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week
trial. Eur Heart J 2010, 31:480-488.
47. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM,
Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P,
Determining the Efficacy and Tolerability Investigators: Determining the
Efficacy and Tolerability Investigators: Safety of anacetrapib in patients
with or at high risk for coronary heart disease. N Engl J Med 2010,
363:2406-2415.
Redondo et al. Lipids in Health and Disease 2011, 10:175
http://www.lipidworld.com/content/10/1/175
Page 7 of 848. Stroes ES, Kastelein JJ, Bénardeau A, Kuhlmann O, Blum D, Campos LA,
Clerc RG, Nisor EJ: Dalcetrapib: no off-target toxicity on blood pressure or
on genes related to the renin-angiotensin-aldosterone system in rats. Br
J Pharmacol 2009, 158:1763-1770.
49. Kuivenhoven JA, de Grooth GJ, Kawamura H, Klerkx AH, Wilhelm F, Trip MD,
Katelein JJ: Effectiveness of inhibition of cholesteryl ester transfer protein
by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J
Cardiol 2005, 95:1085-1088.
50. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K,
Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F,
Chodakewitz J, Gottesdiener KM, Wagner JA: Effect of the cholesteryl ester
transfer protein inhibitor, anacetrapib, on lipoproteins in patients with
dyslipidaemia and on 24-h ambulatory blood pressure in healthy
individuals: two double-blind, randomised placebo-controlled phase I
studies. Lancet 2007, 370:1907-1914.
51. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW,
Sisk CM, Mitchel Y, Pasternak RC: Efficacy and safety of the cholesteryl
ester transfer protein inhibitor anacetrapib as monotherapy and
coadministered with atorvastatin in dyslipidemic patients. Am Heart J
2009, 157:352-360.
52. Ricote M, Valledor AF, Glass CK: Decoding transcriptional programs
regulated by PPARs and LXRs in the macrophage: effects on lipid
homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc
Biol 2004, 24:230-239.
53. Yu L, York J, von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH:
Stimulation of cholesterol excretion by the liver × receptor agonist
requires ATP-binding cassette transporters G5 and G8. J Biol Chem 2003,
278:15565-15570.
54. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA,
Tontonoz P: Control of cellular cholesterol efflux by the nuclear oxysterol
receptor LXR alpha. Proc Natl Acad Sci USA 2000, 97:12097-12102.
55. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT,
Rothblat GH, Rader DJ: Pharmacological activation of liver × receptors
promotes reverse cholesterol transport in vivo. Circulation 2006,
113:90-97.
56. Peng D, Hiipakka RA, Xie JT, Dai Q, Kokontis JM, Reardon CA, Getz GS,
Liao S: A novel potent synthetic steroidal liver × receptor agonist lowers
plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR
(-/-) mice. Br J Pharmacol 2011, 162:1792-1804.
57. Cha JY, Repa JJ: The liver × receptor (LXR) and hepatic lipogenesis. The
carbohydrate-response element-binding protein is a target gene of LXR.
J Biol Chem 2007, 282:743-751.
58. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, Rosenberg RD,
Schrenzel M, Krieger M: Loss of SR-BI expression leads to the early onset
of occlusive atherosclerotic coronary artery disease, spontaneous
myocardial infarctions, severe cardiac dysfunction, and premature death
in apolipoprotein E-deficient mice. Circ Res 2002, 90:270-276.
59. Masson D, Koseki M, Ishibashi M, Larson CJ, Miller SG, King BD, Tall AR:
Increased HDL cholesterol and apoA-I in humans and mice treated with
a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol 2009, 29:2054-2060.
doi:10.1186/1476-511X-10-175
Cite this article as: Redondo et al.: Emerging therapeutic strategies to
enhance HDL function. Lipids in Health and Disease 2011 10:175.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Redondo et al. Lipids in Health and Disease 2011, 10:175
http://www.lipidworld.com/content/10/1/175
Page 8 of 8